{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:35:54Z","timestamp":1778934954971,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009960","name":"Pirkanmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["9AA049"],"award-info":[{"award-number":["9AA049"]}],"id":[{"id":"10.13039\/501100009960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009960","name":"Pirkanmaan Sairaanhoitopiiri","doi-asserted-by":"crossref","award":["MK298"],"award-info":[{"award-number":["MK298"]}],"id":[{"id":"10.13039\/501100009960","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We explored renal cell cancer (RCC) survival among users of antihypertensive medication as hypertension is proposed to be a risk factor for RCC and ACE-inhibitors and angiotensin receptor blockers (ARBs) have been associated with improved prognosis of RCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Finnish cohort of 13,873 participants with RCC diagnosed between 1995\u20132012 was formed from three national databases. RCC cases were identified from Finnish Cancer Registry, medication usage from national prescription database and co-morbidities from Care Registry of Healthcare. Logistic regression was used to calculate odds ratios for metastatic tumor extent at the time of diagnosis. Risk of RCC specific death after diagnosis was analyzed using Cox regression adjusted for tumor clinical characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 5,179 participants died of RCC during the follow-up. No risk association was found for metastatic tumor extent for any drug group. ACE-inhibitors, but no other drug group were associated with decreased risk of RCC specific death overall (HR 0.88, 95% CI 0.82\u20130.95) compared to non-users. In time-dependent analysis high-dose use of ACE-inhibitors (392 Defined Daily Dose (DDD)\/year), HR 0.54, 95% CI 0.45\u20130.66) and ARBs (786.1 DDD\/year, HR 0.66, 95% CI 0.50\u20130.87) associated with improved RCC survival. No information of TNM-classification or tobacco smoking was available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ACE-inhibitors and ARBs in high dose associated with improved RCC specific survival. This may reflect overall benefit of treating hypertension with medication targeting renin-angiotensin system (RAS) system among RCC patients. Further studies are needed to explore the role of RAS in RCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10552-021-01527-w","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T09:02:19Z","timestamp":1639818139000},"page":"313-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system"],"prefix":"10.1007","volume":"33","author":[{"given":"Tommi","family":"Eskelinen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thea","family":"Veitonm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Kotsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo L. J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"P\u00f6yh\u00f6nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teemu J.","family":"Murtola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"key":"1527_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, in press.","DOI":"10.3322\/caac.21492"},{"key":"1527_CR2","unstructured":"Finnish Cancer Registry. https:\/\/cancerregistry.fi\/statistics\/cancer-statistics\/. Last visited 20.5.2019."},{"issue":"3","key":"1527_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3109\/21681805.2016.1151460","volume":"50","author":"E Mariusdottir","year":"2016","unstructured":"Mariusdottir E, Ingimarsson JP, Jonsson E, Einarsson GV, Aspelund T, Gudnason V, Gudbjartsson T (2016) Occupation as a risk factor for renal cell cancer: a nationwide, prospective epidemiological study. Scand J Urol 50(3):181\u2013185","journal-title":"Scand J Urol"},{"issue":"1","key":"1527_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/MOU.0000000000000454","volume":"28","author":"R Tahbaz","year":"2018","unstructured":"Tahbaz R, Schmid M, Merseburger AS (2018) Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr Opin Urol 28(1):62\u201379","journal-title":"Curr Opin Urol"},{"key":"1527_CR5","first-page":"1","volume":"26","author":"TJ Eskelinen","year":"2017","unstructured":"Eskelinen TJ, Kotsar A, Tammela TLJ, Murtola TJ (2017) Components of metabolic syndrome and prognosis of renal cell cancer. Scand J Urol 26:1\u20137","journal-title":"Scand J Urol"},{"key":"1527_CR6","unstructured":"Terveys, toimintakyky ja hyvinvointi Suomessa: FinTerveys 2017 -tutkimus. 2018(2018_004)."},{"issue":"2","key":"1527_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/157488607780598296","volume":"2","author":"G Corrao","year":"2007","unstructured":"Corrao G, Scotti L, Bagnardi V, Sega R (2007) Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf 2(2):125\u2013133","journal-title":"Curr Drug Saf"},{"issue":"5","key":"1527_CR8","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/ije\/23.5.923","volume":"23","author":"A Mellemgaard","year":"1994","unstructured":"Mellemgaard A, Niwa S, Mehl ES, Engholm G, McLaughlin JK, Olsen JH (1994) Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol 23(5):923\u2013930","journal-title":"Int J Epidemiol"},{"issue":"1","key":"1527_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/sj.bjc.6603823","volume":"97","author":"LJ Vatten","year":"2007","unstructured":"Vatten LJ, Trichopoulos D, Holmen J, Nilsen TI (2007) Blood pressure and renal cancer risk: the HUNT Study in Norway. Br J Cancer 97(1):112\u2013114","journal-title":"Br J Cancer"},{"issue":"4","key":"1527_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/aje\/kwm321","volume":"167","author":"S Weikert","year":"2008","unstructured":"Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A, Overvad K, Becker N, Linseisen J, Trichopoulou A, Mountokalakis T, Trichopoulos D, Sieri S, Palli D, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Verschuren WM, Ljungberg B, Riboli E (2008) Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 167(4):438\u2013446","journal-title":"Am J Epidemiol"},{"key":"1527_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2017.07.001","volume":"83","author":"M Nayan","year":"2017","unstructured":"Nayan M, Juurlink DN, Austin PC, Macdonald EM, Finelli A, Kulkarni GS, Hamilton RJ (2017) Medication use and kidney cancer risk: a population-based study. Eur J Cancer 83:203\u2013210. https:\/\/doi.org\/10.1016\/j.ejca.2017.07.001","journal-title":"Eur J Cancer"},{"issue":"5","key":"1527_CR12","first-page":"5059","volume":"14","author":"P Sobczuk","year":"2017","unstructured":"Sobczuk P, Szczylik C, Porta C, Czarnecka AM (2017) Renin angiotensin system deregulation as renal cancer risk factor. Oncol Lett 14(5):5059\u20135068","journal-title":"Oncol Lett"},{"key":"1527_CR13","unstructured":"Finnish Cancer Registry, https:\/\/cancerregistry.fi\/statistics\/, last visited 2.7.2020"},{"key":"1527_CR14","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology, https:\/\/www.whocc.no\/atc_ddd_index\/, last visited 20.5.2019"},{"issue":"5","key":"1527_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"key":"1527_CR16","unstructured":"IBM Corp. Released 2016. IBM SPSS Statistics for Macintosh, Version 24.0. Armonk, NY: IBM Corp."},{"issue":"9","key":"1527_CR17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1593\/neo.07418","volume":"9","author":"C R\u00f6cken","year":"2007","unstructured":"R\u00f6cken C, Neumann K, Carl-McGrath S, Lage H, Ebert MP, Dierkes J, Jacobi CA, Kalmuk S, Neuhaus P, Neumann U (2007) The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. Neoplasia 9(9):716\u2013722","journal-title":"Neoplasia"},{"issue":"2","key":"1527_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0006-291X(02)00496-5","volume":"294","author":"M Fujita","year":"2002","unstructured":"Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces growth, angiogenesis and metastasis. Biochem Biophys Res Commun 294(2):441\u2013447","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1527_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/000313480707300307","volume":"73","author":"JH Heinzerling","year":"2007","unstructured":"Heinzerling JH, Anthony T, Livingston EH, Huerta S (2007) Predictors of distant metastasis and mortality in patients with stage II colorectal cancer. Am Surg 73(3):230\u2013238","journal-title":"Am Surg"},{"issue":"3","key":"1527_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/jch.12273","volume":"16","author":"Y Li","year":"2014","unstructured":"Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J, Zhang D, Guo H, Shi B (2014) Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 16(3):177\u2013185","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"1527_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3747\/co.19.972","volume":"19","author":"P Larochelle","year":"2012","unstructured":"Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F, Ruether D, Myers M, Bjarnason G (2012) Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. Curr Oncol 19(4):202\u2013208","journal-title":"Curr Oncol"},{"issue":"9","key":"1527_CR22","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/ijc.29972","volume":"138","author":"MJ Sorich","year":"2016","unstructured":"Sorich MJ, Kichenadasse G, Rowland A, Woodman RJ, Mangoni AA (2016) Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treatedwith VEGF-targeted therapy: a pooled secondary analysis of clinical trials. Int J Cancer 138(9):2293\u20132299","journal-title":"Int J Cancer"},{"issue":"5","key":"1527_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyc MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913\u2013924","journal-title":"Eur Urol"},{"issue":"1","key":"1527_CR24","doi-asserted-by":"publisher","first-page":"36.e1","DOI":"10.1016\/j.urolonc.2016.08.013","volume":"35","author":"WP Parker","year":"2017","unstructured":"Parker WP, Lohse CM, Zaid HB, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH (2017) Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma. Urol Oncol 35(1):36.e1-36.e6","journal-title":"Urol Oncol"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01527-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-021-01527-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01527-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T07:29:50Z","timestamp":1642663790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-021-01527-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,18]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1527"],"URL":"https:\/\/doi.org\/10.1007\/s10552-021-01527-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-935735\/v1","asserted-by":"object"}]},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,18]]},"assertion":[{"value":"17 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}